v3.25.3
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash Flows from Operating Activities    
Net loss $ (5,869,163) $ (5,302,205)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 76,176 85,590
Stock-based compensation 973,801 1,240,982
Amortization of intangible assets 571,347 571,347
Amortization of product development costs 326,676 221,207
Amortization of software development costs 524,226 248,203
Loss on disposal of fixed assets 1,443 1,654
Change in unrealized gain on investments (44,009)
Changes in operating assets and liabilities:    
Accounts receivable (3,906) (102,886)
Inventory (170) 358,739
Prepaid expenses and other current assets (262,976) (26,313)
Accounts payable (215,026) (644,091)
Accrued expenses 198,326 (63,802)
Deferred revenue 303,499 150,007
Net Cash Used in Operating Activities (3,419,756) (3,261,568)
Cash Flows from Investing Activities    
Purchase of equipment and website development (22,373) (23,201)
Product development costs (92,323) (339,402)
Software development costs (975,373) (686,761)
Redemption/sale of government securities 2,317,411
Purchase of investments in government securities (9,841,468)
Net Cash Used in Investing Activities (8,614,126) (1,049,364)
Cash Flows from Financing Activities    
Proceeds from the sale of common stock and warrants 14,377,835 4,492,198
Fees paid in connection with equity offerings (1,830,459) (772,580)
Common stock withheld to pay taxes (4,235)
Proceeds from exercise of warrants for common stock 22,147 8,220
Series C redeemable preferred stock dividends (225,000) (225,000)
Net Cash Provided by Financing Activities 12,344,523 3,498,603
Net Increase (Decrease) in Cash and Cash Equivalents 310,641 (812,329)
Cash and Cash Equivalents - Beginning of Period 3,806,915 6,398,164
Cash and Cash Equivalents - End of Period 4,117,556 5,585,835
Non-cash investing and financing activities:    
Series H preferred stock conversion to common stock 472,245
Website development costs included in accounts payable 9,802
Fees in connection with offering costs included in accounts payable and accrued expenses 188,120
Fees in connection with deferred costs related to a reverse stock split included in accounts payable and accrued expenses 38,944
Product development costs included in accounts payable and accrued expenses 17,004 104,243
Software development costs included in accounts payable and accrued expenses 62,331 89,379
Lease liabilities and right-of-use assets arising from lease extension $ 331,944